Updates in HCM Management: An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023
Published: 31 August 2023
-
Views:
14054
-
Likes:
7
-
Views:
14054
-
Likes:
7
Overview
This programme features the chairpersons responsible for the most recent ESC Guidelines on Cardiomyopathy, which were presented at ESC 2023 in Amsterdam.
Prof Elena Arbelo (University of Barcelona, ES) and Prof Juan Pablo Kaski (University College London, UK) offer comprehensive insights into the updated guidelines. They delve into the latest developments in hypertrophic cardiomyopathy (HCM), provide treatment recommendations for obstructive hypertrophic cardiomyopathy (oHCM), and discuss how these new guidelines impact the current approach to managing these conditions.
This session is tailored to assist healthcare practitioners in comprehending the most recent guidelines recommendations and ensuring their effective implementation. The authors explore how medical practices can adapt to incorporate new therapeutic agents for oHCM and clarify the responsibilities associated with prescribing these therapies.
This programme holds particular educational value for Cardiologists, Heart Failure Specialists, Electrophysiologists, and Cardiac Surgeons. Furthermore, it will be of interest to any HCPs specialising in HCM treatment or those who may play a role within the broader care team by identifying and referring patients for specialist assessments on a global scale.
Learning Objectives
- Recall guideline updates relevant to the use of disease modifying agents in hypertrophic cardiomyopathy
- Identify patients who, according to guidelines, may benefit from emerging disease modifying therapies prior to septal ablation therapy or being managed by symptom control alone
- Discuss long-term management strategies for patients receiving myosin inhibitor therapy
Target Audience
- Cardiologists
- Heart Failure Specialists
- Electrophysiologists
- Cardiac Surgeons
- HCPs who specialise in treating HCM
More from this programme
Part 1
What’s New for HCM?
Prof Elena Arbelo and Prof Juan Pablo Kaski reveal updated HCM guidelines, offer oHCM treatment insights, and discuss condition management.
| 1 session | |
| What’s New for HCM? | Watch now |
Part 2
Practical Implications for Practitioners
This session is designed to help healthcare professionals understand the latest guidelines recommendations and effectively implement them.
Part 3
Q&A
Part 4
Downloadable Asset
Faculty Biographies
Juan-Pablo Kaski
Associate Professor
Prof Kaski is an Associate Professor at the Centre for Inherited Cardiovascular Diseases, UCL, London, UK. He is also a consultant paedriatric cardiologist, and Director of the Inherited Cardiovascular Diseases Unit at the Great Ormond Street Hospital for Children NHS Trust, UK.
For his work on the genetic basis of pre-adolescent hypertrophic cardiomyopathy, Prof Kaski was awarded the Young Investigator Award by the European Society of Cardiology (ESC) in 2008.
Prof Kaski's research interests include cardiomyopathies, inherited arrhythmias, aortopathy syndromes and rare cardiovascular genetic diseases. His main focuses include heart muscle disease, ion channel diseases, sudden cardiac death and Marfan syndrome.
Prof Juan-Pablo Kaski is on the Editorial Board of European Cardiology Review, in addition to other leading journals.
Elena Arbelo
Associate Professor
Prof Elena Arbelo is a Cardiac Electrophysiologist at Hospital Clínic of Barcelona, Barcelona, Spain, where she serves as Coordinator of the Cardiac Genetic Diseases and Sudden Arrhythmic Death Unit.
She is a Clinical Professor at the University of Barcelona and a researcher at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Prof Arbelo is a member of several committees of the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), and the Heart Rhythm Society (HRS).
Prof Arbelo is a committee member for several large-scale European Registries to gather data on atrial fibrillation and guideline implementation. She serves as a member of the Working Group on Atrial Fibrillation of the International Consortium for Health Outcomes Measurement (ICHOM).
Prof Arbelo is an editorial board member of Arrhythmia & Electrophysiology Review journal.
Comments